by Isogenica Webmaster | Oct 2019 | Press Releases, Welcome
Isogenica appoints Dr Bjӧrn Cochlovius to the Board of Directors Dr Cochlovius joins Isogenica as a non-executive director replacing Dr Gӧran Forsberg, who stepped down from the Board on October 11, 2019. Dr Forsberg has served as a non-executive director since... by Isogenica Webmaster | Sep 2019 | Press Releases, Welcome
Isogenica appoints Dr David Mead as Director of Business Development Isogenica today announced the appointment of Dr David Mead as Director of Business Development effective immediately. Dr Mead was previously Business Development Director at Albumedix where he was... by Isogenica Webmaster | Aug 2019 | Welcome
Isogenica expands team Isogenica is hiring to add strength and depth to our team and to increase our commitment to partnerships with biopharma. View our careers Isogenica is increasing our commitment to partnerships with biopharma. We’ve seen important shifts in the... by Isogenica Webmaster | Jan 2019 | Press Releases, Welcome
Isogenica expands collaboration with Aro Biotherapeutics Isogenica today announced an expansion of the collaboration and license agreement signed with Aro Biotherapeutics in June 2018. Under the expanded agreement, Isogenica will use its CIS Display platform to help... by Isogenica Webmaster | Sep 2018 | Press Releases, Welcome
Isogenica appoints Dr Emma Sceats as Chief Executive Officer Isogenica Ltd, a leader in the design and construction of diverse, fully synthetic, antibody libraries for biopharmaceutical discovery, today announced that Dr Emma Sceats has been appointed Chief Executive... by Isogenica Webmaster | Jul 2018 | Welcome
Isogenica licenses CIS Display Technology Isogenica Ltd today announced that it has signed a new licensing agreement with Aro Biotherapeutics Company (Aro) of Philadelphia. USA, that will leverage each other’s strengths in recombinant protein technologies and...